Nikolaos C.George Ph.D. (Nick)

Partner

New York + 1.212.326.3887

Connect:

Share

Nick George has more than 30 years of experience developing and evaluating biologics-based patent portfolios.

Nick has devised worldwide patent prosecution strategies for dozens of pre-clinical, clinical, and approved products involving such diverse technologies as therapeutic antibodies, antibody drug conjugates (ADCs), chimeric antigen receptors (CARs), cellular therapeutics (including natural killer [NK], macrophage, monocyte, regulatory T [Treg] cell, and induced pluripotent stem cell [iPSC] therapeutics), gene therapies, gene editing, oncolytic viruses, RNA (ribonucleic acid) therapeutics, peptide therapeutics, diagnostics, and enzyme replacements.

Nick also routinely conducts freedom-to-operate, noninfringement, invalidity, and patentability assessments and performs IP diligence in connection with investments, partnerships, licensing, and private and public financings.

He advises clients ranging from emerging company start-ups to mid- and large-cap biotech and pharmaceutical companies, as well as life sciences venture capital and incubator firms.

Nick holds a Ph.D. in genetics from the University of California, Berkeley and prior to entering patent law did postdoc research at Columbia University (The Chalfie Lab).

Experience

  • Coya Therapeutics announces its initial public offeringJones Day represented Coya Therapeutics Inc. as IP counsel in connection with its December 2022 initial public offering.
  • Celldex Therapeutics develops worldwide patent portfolios for anti-tyrosine kinase receptor therapeutic antibodiesJones Day is representing Celldex Therapeutics, Inc. in connection with the development and prosecution of global portfolios related to the company's lead clinical and pre-clinical anti-tyrosine kinase receptor therapeutic antibodies.
  • Turnstone Biologics develops patent portfolios for its oncolytic virus clinical candidateJones Day is representing Turnstone Biologics Corp. in the development of patent portfolios covering its oncolytic virus programs.
  • ToolGen faces off in two patent interferences involving CRISPR/Cas9 applicationJones Day is representing ToolGen, Inc. in two patent interferences involving CRISPR/Cas9 technology.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • ToolGen seeks patent protection for CRISPR technologyJones Day is prosecuting patent applications and developing a patent portfolio on behalf of ToolGen, Inc. for CRISPR technology.
  • RaNA Therapeutics (now known as Translate Bio) acquires Shire's messenger RNA therapy platformJones Day acted as IP counsel to RaNA Therapeutics, Inc. (now known as Translate Bio) in connection with its acquisition of Shire Pharmaceuticals' messenger RNA therapy platform (MRT), with lead programs in cystic fibrosis and urea cycle disorders.
  • Celgene develops worldwide patent portfolios covering CAR-T and other cellular therapeuticsJones Day is advising Celgene Corporation in the strategic development of worldwide patent portfolios covering CAR-T and other cellular therapeutics.
  • Celgene develops patent portfolio for anti-CD47 therapeutic antibodiesJones Day represented Celgene Corporation in the development of a portfolio of patents directed to anti-CD47 therapeutic antibodies.
  • Genzyme (Sanofi) develops patent portfolio for antisense drug Kynamro®Jones Day represented Genzyme Corporation (Sanofi) in developing patent portfolios related to the apolipoprotein B-targeting antisense drug, Kynamro® (mipomersen), which was the first antisense drug to reach the market and used for the treatment of homozygous familial hypercholesterolemia.
  • Celgene enters strategic collaboration with MedImmune for hematologic malignanciesJones Day acted as special patent counsel, IP technology transaction counsel, and tax counsel on Celgene Corporation's strategic collaboration with MedImmune regarding human monoclonal antibody MEDI-4736 directed to PD-L1 to allow the immune system to continue to fight blood cancers.
  • Kirin Pharma Kabushiki Kaisha establishes patent portfolio for human LIGHT antibodiesJones Day represented Kirin Pharma Kabushiki Kaisha and Kirin Pharma USA, Inc. in the development of its patent portfolio and prosecution strategies related to human LIGHT antibodies.
  • PDL BioPharma goes head to head against UCB Pharma in patent interference involving reshaped humanized immunoglobulinsJones Day represented PDL BioPharma, Inc. in patent interference against UCB Pharma S.A. involving "reshaped" humanized immunoglobulins.
    • View All

    Additional Speaking Engagements

    • October 19, 2022
      East-West Biopharma Summit Road Trip, New York City, October 19, 2022

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.